Amneal Pharmaceuticals: Q4 Earnings Insights - Amneal Pharmaceuticals (NASDAQ:AMRX)

Amneal Pharmaceuticals AMRX reported its Q4 earnings results on Friday, March 1, 2024 at 06:00 AM.

Here's what investors need to know about the announcement.

Amneal Pharmaceuticals beat estimated earnings by 56.00000000000001%, reporting an EPS of $0.14 versus an estimate of $0.09.

Revenue was up $7.22 million from the same period last year.

Last quarter the company beat on EPS by $0.06 which was followed by a 6.0% drop in the share price the next day.

Here's a look at Amneal Pharmaceuticals's past performance:

Quarter	Q3 2023	Q2 2023	Q1 2023	Q4 2022
EPS Estimate	0.13	0.10	0.10	0.21
EPS Actual	0.19	0.19	0.12	0.23
Revenue Estimate	595.27M	562.49M	537.31M	579.91M
Revenue Actual	620.04M	599.05M	557.54M	609.76M

New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).

Amneal Pharmaceuticals management provided guidance for FY 2024, expecting earnings between $0.53 and $0.63 per share.

To track all earnings releases for Amneal Pharmaceuticals visit their earnings calendar here.

This article was generated by Benzinga's automated content engine and reviewed by an editor.